Clinical application of citicolinum and its role in homeostasis of neurons cellular membranes and effector organs

Authors

  • V.V. Afanasiev Saint-Peterburg medical Academy of postgraduate education

DOI:

https://doi.org/10.22141/2224-0586.1.72.2016.74450

Keywords:

citicoline, choline homeostasis, homeostasis of cellular membranes

Abstract

The article describesmechanisms of action, pharmacological effectsand clinical features of Citicoline administration. Givenits role in the homeostasisof cellular membranesof neuronsand organs(effectors), ensuring theframeand matrix propertiesof biological cell membranes, homeostasisof choline.

Downloads

Download data is not yet available.

Author Biography

V.V. Afanasiev, Saint-Peterburg medical Academy of postgraduate education

Department of emergency medicine

References

Аничков С.В. Избирательное действие медиаторных средств. — М.: Мед, 1971. — 312.

Базаревич Г.Я., Богданович Г.С., Волкова Н.А. Нейромедиаторы в регуляции внешнего дыхания. — М.: Мед. — 25-68.

Денисенко П.П. Роль холинореактивных систем в регуляторных процессах. — М.: Мед, 1980. — 296.

Кольман Я., Рем К. Наглядная биохимия. — М.: Мир, 2000. — 469.

Никонов В.В., Савицкая И.Б. Новые возможности комбинированной нейропротекции при ишемическом инсульте // Нейронауки: теоретичні і практичні аспекти. — 2007. — 3. — 1-2, 85-88.

Румянцева С.А., Силина Е.В., Афанасьев В.В. Невропатология и психиатрия. — 2009. — 109. — 3. — 64-68.

Скворцова В.И., Боцина А.В. Нейропротективная терапия в остром периоде церебрального инсульта // Врач. — 2007. — 12. — 25-28.

Adibhatla R.M., Hatcher J. Role of lipids in brain injury and diseases // Future Lipidol. — 2007. — 2. — 4. — 403-422.

Advenier C., Rigoli D. Antihistaminiques // Sem. Hop. — V. 63, № 21. — Р. 1699-1710.

Agnoli A., Ruggieri S., Denaro A. et al. New strategies in the management of Parkinson’s disease: a biological approach using a phospholipid precursor (CDP-choline) // Neuropsychobiology. — 1982. — 8. — 289-296.

Andersen M. et al. // Stroke. — 1999. — 30. — 1464-71.

Cacabelos R., Alvarez X.A., Franco-Maside A. et al. Effect of CDP-choline on cognition and immune function in Alzheimer's disease and multi-infarct dementia // Ann. NY Acad. Sci. — 1993. — 695. — 321-323.

Cancev M., Yilmaz M., Ilcol Y. Cardiovascular effects of CDP-Choline and its metabolites: involvement of peripheral autonomic nervious systrm // Eur. J. Pharmacol. — 2007. — 577. — 1-3, 129-142.

Ceda et al. Alpha Glycerylphosphorylcholine administration increases the GH responses to GHRH of young and elderly subjects // Horm. Metab. Res. — 1991. — 24. — 3. — 119-21.

Cohadon F. et al. // Nourochirurgie. — 1982. — 28. — 287-290.

Davalos A., Castillo J., Alvares-Sabin et al. // Stroke. — 2002. — 33. — 12. — 2850-2857.

di Perri R., Coppola G., Ambrosio L.A. et al. A multicentre trial to evaluate the efficacy and tolerability of a-glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia // J. Int. Med. Res. — 1991. — 19. — 330-341.

Dinsdale J.R.M., Griffiths G.K., Castello J. et al. CDP-choline: repeated oral dose tolerance studies in adult healthy volunteers // Arzneimittelforschung. — 1983. — 33. — 1061-1065.

Eberhardt R., Birbamer G., Gerstenbrand F. et al. Citicoline in the treatment of Parkinson's disease // Clin. Ther. — 1990. — 12. — 489-495.

Fernandez R.L. Efficacy and safety of oral CDP-choline // Arzneimittelforschung. — 1983. — 33. — 1073-1080.

Garcia-Mas A., Rossinol A., Roca M. et al. Effects of citicholine in subcortical dementia associated with Parkinson’s disease assessed by quantified electroencephalography // Clin. Ther. — 1992. — 14. — 718-729.

Gelenberg A.J., Dorer D.J., Wojcik J.D. et al. A crossover study of lecithin treatment of tardive dyskinesia // J. Clin. Psychiatry. — 1990. — 51. — 149-153.

Goas J.Y. et al. Symposium International: Souff rance Cerebrale et Precurseurs des Phospholipides (Jan 18 Paris), 1980.

Li Z., Agellon L., Vance D. Thematic review series; glyceroli­pids. Phosphatidylcholine and choline homeostasis // J. Lipid. Res. — 2008. — 49. — 6. — 1187-1194.

Marti J.F., Urtasun M. Citicoline in the treatment of Parkinson’s disease // Clin. Ther. — 1991. — 13. — 239-242.

Micromedex, Inc., Drugdex., 2009.

Spagnoli A. & Tognoni G. 'Cerebroactive' drugs: clinical pharmacology and therapeutic role in cerebrovascular disorders // Drugs. — 1983. — 26. — 44-69.

Suno M. et al. // Yakuri to Chiryo. — 1985. — 13. — 10. — 165-170.

Tazaki Y., Sakai F., Otomo E. et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study // Stroke. — 1988. — 19. — 211-216.

Schabitz W.R. // J. Neurol. Sci. — 1996. — 138. — 21-25.

Wurtman R.J. Choline metabolism as a basis for the selective wulnerability of cholinergic neurons // Trends Neurosciences. — 1992. — 15. — 117-122.

Published

2022-01-27

How to Cite

Afanasiev, V. (2022). Clinical application of citicolinum and its role in homeostasis of neurons cellular membranes and effector organs. EMERGENCY MEDICINE, (1.72), 46–50. https://doi.org/10.22141/2224-0586.1.72.2016.74450

Issue

Section

Scientific Review